Nasdaq-EEX Deal Hits Snag: Reportedly Risks Full-Scale Investigation By EU Antitrust Regulators
EU may investigate Nasdaq and EEX deal unless Deutsche Boerse improves competition measures. Nasdaq Power acquisition aims to serve Nordics.
EXCLUSIVE: Tema American Reshoring ETF Outshines S&P 500 Without Owning Magnificent 7 Stocks — ‘They Can No Longer Manufacture In China’
RSHO ETF beats S&P 500 in the last year without holding any 'Magnificent Seven' stocks. ETF invests in reshoring trend driven by supply chain insecurity and government policy.
Why Coherent Shares Are Seeing Blue Skies Today
Jim Anderson appointed CEO of Coherent Corp. succeeding retiring CEO Dr. Mattera. Coherent recently launched new laser sensor.
VIX Spikes 8% As Stocks Sink; Bonds, Gold Rise On Growth Concerns; Meme Stocks Roar, Peso Plummets: What’s Driving Markets Monday?
All major U.S. equity indices opened the week with losses, as traders shifted to safe-haven bonds and gold amid concerns affecting the health of the U.S. manufacturing activity.
Why US Drug Giant Bristol Myers Squibb Stock Trading Up On Monday
Bristol Myers Squibb's KRYSTAL-12 study reveals Krazati's significant benefits over chemotherapy for KRASG12C-mutated NSCLC, improving progression-free survival and response rates.
Nucor Expands Beyond Steelmaking With Acquisition Of Rytec: Details
Nucor to acquire Rytec Corporation for $565 million, expanding its product portfolio and downstream businesses.
Johnson & Johnson At ASCO Highlights Long Term Data From Multiple Myeloma Drug, Shows Sustained Deep, Durable Responses In Pretreated Patients
JNJ announced positive longer-term data from Phase 1/2 study of Tecvayli for RRMM. Results show deep and durable responses with a consistent safety profile.
Ericsson Turns The Corner: Reports Conclusion Of US Anti-Corruption Compliance Monitorship
Ericsson shares up after independent monitor concludes compliance work and the March 2023 Plea Agreement with the DOJ that followed non-criminal breaches of the DPA has also expired as of June 2.
Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients
Moderna and Merck's Phase 2b study results for mRNA-4157 combined with Keytruda, showing improvements in recurrence-free and distant metastasis-free survival for high-risk melanoma patients. Phase 3 trials are now underway for melanoma and non-small cell lung cancer.
Zantac Heart Burn Continues For GSK As US Court Ruling Allows Thousands Of Zantac Lawsuits To Move Forward
GSK shares fell as the Delaware State Court allowed over 70,000 lawsuits regarding the discontinued heartburn drug Zantac (ranitidine) to proceed. This ruling contradicts a Federal Court's 2022 decision dismissing similar cases, potentially increasing GSK's liability.